Canada’s Drug Agency (CDA-AMC) recommends that Calquence should be reimbursed by public drug plans for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplant (ASCT) in combination with bendamustine and rituximab (BR), if certain conditions are met.
